Sugi Predict

Sugi Predict / Compounds / SCHEMBL30369652

SCHEMBL30369652

SCHEMBL30369652

CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C

nearest known ligand 0.63

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 15/20 0.63
▸ CTSD P07339 2/20 0.58
▸ BACE2 Q9Y5Z0 3/20 0.56
▸ VIPR2 P41587 3/20 0.56
▸ VIPR1 P32241 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30368966 0.97 BACE1 (0.59) BACE1CTSDBACE2VIPR2
SCHEMBL30369274 0.92 BACE1 (0.67) BACE1CTSDBACE2
SCHEMBL30369388 0.92 BACE1 (0.68) BACE1CTSDBACE2
SCHEMBL29414490 0.90 BACE1 (0.64) BACE1CTSDBACE2
SCHEMBL30423123 0.89 BACE1 (0.59) BACE1CTSDBACE2VIPR1
SCHEMBL30369306 0.89 BACE1 (0.71) BACE1CTSDBACE2
SCHEMBL29777765 0.89 BACE1 (0.59) BACE1CTSDBACE2
SCHEMBL30974316 0.89 VIPR1 (0.60) BACE1CTSDBACE2VIPR2VIPR1
SCHEMBL30369032 0.89 BACE1 (0.72) BACE1CTSDBACE2
SCHEMBL29443821 0.88 BACE1 (0.65) BACE1CTSDBACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4159745-B1 S100A8-INHIBITING PEPTIDE AND THERAPEUTIC DRUG FOR DISEASE WHICH CONTAINING SAME UNIV TOKYO WOMENS MEDICAL (JP) 2025-09-24 — — EP disclosed
US-20230220005-A1 S100A8-INHIBITING PEPTIDE AND DISEASE THERAPEUTIC AGENT CONTAINING SAME TOKYO WOMEN'S MEDICAL UNIVERSITY (JP) 2023-07-13 — — US disclosed
EP-4159745-A1 S100A8-INHIBITING PEPTIDE AND THERAPEUTIC DRUG FOR DISEASE WHICH CONTAINING SAME Tokyo Women's Medical University (JP) 2023-04-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230220005-A1 S100A8-INHIBITING PEPTIDE AND DISEASE THERAPEUTIC AGENT CONTAINING SAME S100A8, S100A11, S100A4 BACE1 1524/4885CTSD 1443/4885BACE2 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.